-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Royalty Pharma plc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q2 2019 to Q3 2024.
- Royalty Pharma plc Nonoperating Income (Expense) for the quarter ending September 30, 2024 was $71.3M.
- Royalty Pharma plc Nonoperating Income (Expense) for the twelve months ending September 30, 2024 was $170M.
- Royalty Pharma plc annual Nonoperating Income (Expense) for 2023 was $208M.
- Royalty Pharma plc annual Nonoperating Income (Expense) for 2022 was -$77M, a 59.4% increase from 2021.
- Royalty Pharma plc annual Nonoperating Income (Expense) for 2021 was -$190M, a 278% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)